Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- A preclinical study indicates that Conatumumab, a cancer drug, can effectively treat peripheral artery disease (PAD) by promoting the growth of new blood vessels. - The study demonstrated that Conatumumab can bypass arterial blockages and restore blood flow in affected limbs, offering a potential limb-saving treatment. - Researchers observed the drug's efficacy in preclinical models and in vitro, using cells and arteries from PAD patients who underwent amputation. - Given the existing safety profile of Conatumumab from its use in cancer treatment, human trials could potentially proceed rapidly.
- Preclinical studies demonstrate that Conatumumab, previously tested as a cancer drug, effectively treats Peripheral Artery Disease (PAD). - The drug was tested in preclinical models of PAD and in vitro using cells and arteries from PAD patients who underwent amputation. - Safety and toxicology studies already completed for Conatumumab in cancer treatment expedite its potential transition to human trials for PAD. - Researchers are optimistic about rapidly advancing to clinical trials, given the established safety profile and promising preclinical results.
